To test the hypothesis that sympatholytic antihypertensive antihypertensive therapy
(αβ-blocker - carvedilol) will reduce out-of-clinic ambulatory BP to a greater extent by
blocking sympathetic activity than non-sympatholytic antihypertensive medication
(dihydropyridine calcium channel blocker - amlodipine) in individuals with masked
hypertension.